These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 25164277)

  • 21. Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPARα/δ Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.
    Feng Z; Xiang J; Liu H; Li J; Xu X; Sun G; Zheng R; Zhang S; Liu J; Yang S; Xu Q; Wen X; Yuan H; Sun H; Dai L
    J Med Chem; 2022 Feb; 65(3):2571-2592. PubMed ID: 35060744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring the protective effect of ShengMai-Yin and Ganmaidazao decoction combination against type 2 diabetes mellitus with nonalcoholic fatty liver disease by network pharmacology and validation in KKAy mice.
    Li S; Qian Y; Xie R; Li Y; Jia Z; Zhang Z; Huang R; Tuo L; Quan Y; Yu Z; Liu J; Xiang M
    J Ethnopharmacol; 2019 Oct; 242():112029. PubMed ID: 31216433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis.
    Siddiqui MS; Parmar D; Sheikh F; Sarin SK; Cisneros L; Gawrieh S; Momin T; Duseja A; Sanyal AJ
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2597-2605.e2. PubMed ID: 36731585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolving therapies for non-alcoholic steatohepatitis.
    Tilg H; Moschen AR
    Expert Opin Drug Discov; 2014 Jun; 9(6):687-96. PubMed ID: 24766298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between resistin +299A/A genotype and nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus.
    Zhang LY; Jin YJ; Jin QS; Lin LY; Zhang DD; Kong LL
    Gene; 2013 Oct; 529(2):340-4. PubMed ID: 23954219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aleglitazar, a dual PPARα and PPARγ agonist for the potential oral treatment of type 2 diabetes mellitus.
    Lecka-Czernik B
    IDrugs; 2010 Nov; 13(11):793-801. PubMed ID: 21046527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PPARs as therapeutic targets in cardiovascular disease.
    van Bilsen M; van Nieuwenhoven FA
    Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
    Ding SY; Tigno XT; Braileanu GT; Ito K; Hansen BC
    Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice.
    Yang H; Yang T; Heng C; Zhou Y; Jiang Z; Qian X; Du L; Mao S; Yin X; Lu Q
    Phytother Res; 2019 Dec; 33(12):3140-3152. PubMed ID: 31452288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A nonthiazolidinedione peroxisome proliferator-activated receptor α/γ dual agonist CG301360 alleviates insulin resistance and lipid dysregulation in db/db mice.
    Jeong HW; Lee JW; Kim WS; Choe SS; Shin HJ; Lee GY; Shin D; Lee JH; Choi EB; Lee HK; Yon GH; Cho B; Kim HR; Choi SH; Chung YS; Park SB; Chung H; Ro S; Kim JB
    Mol Pharmacol; 2010 Nov; 78(5):877-85. PubMed ID: 20724462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Hyogo H; Yamagishi S; Maeda S; Kimura Y; Ishitobi T; Chayama K
    Dig Liver Dis; 2012 Jun; 44(6):492-6. PubMed ID: 22265683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PPAR Agonists and Metabolic Syndrome: An Established Role?
    Botta M; Audano M; Sahebkar A; Sirtori CR; Mitro N; Ruscica M
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29662003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sex-specific differences in Type 2 Diabetes Mellitus and dyslipidemia therapy: PPAR agonists.
    Benz V; Kintscher U; Foryst-Ludwig A
    Handb Exp Pharmacol; 2012; (214):387-410. PubMed ID: 23027460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease.
    Raschi E; Mazzotti A; Poluzzi E; De Ponti F; Marchesini G
    Expert Opin Pharmacother; 2018 Dec; 19(17):1903-1914. PubMed ID: 30299993
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C333H, a novel PPARalpha/gamma dual agonist, has beneficial effects on insulin resistance and lipid metabolism.
    Xu C; Wang LL; Liu HY; Zhou XB; Cao YL; Li S
    Acta Pharmacol Sin; 2006 Feb; 27(2):223-8. PubMed ID: 16412273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].
    Чопей ІВ; Івачевська ВВ; Чубірко КІ; Гряділь ТІ; Гечко ММ
    Wiad Lek; 2017; 70(2):169-173. PubMed ID: 28511152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.
    Carmena R
    Am Heart J; 2005 Nov; 150(5):859-70. PubMed ID: 16290951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.